NCT03446495 - An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

March 20, 2019

Study Completion Date

May 20, 2019

Conditions

Ovarian Cancer

Interventions

DRUG

Trabectedin + PLD

Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.

Trial Locations (10)

Unknown

RECRUITING

Almaty oncological center, Almaty

RECRUITING

Almaty regional oncological dispensary, Almaty

RECRUITING

Kazakh institute of oncology and radiology, Almaty

RECRUITING

Kazakh institute of oncology and radiology, Almaty

RECRUITING

Astana Oncology Center, Astana

RECRUITING

Kyzylorda regional Oncological center, Kyzylorda

RECRUITING

West Kazakhstan regional oncology dispensary, Oral

RECRUITING

North Kazakhstan Regional Oncology Center, Petropavl

RECRUITING

South Kazakhstan regional oncologic dispensary, Shymkent

RECRUITING

East Kazakhstan Regional Oncology Dispensary, Ust-Kamenogorsk